Tatva Chintan Pharma Chem Ltd Q1 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/1f7dilnm4fl6iv9tgpj6p728.pdf

Key Takeaways


Dahej Expansion & Capacity Utilization


Margin Walk & Inventory Overhang

Chintan Shah: "We are still in a process of clearing of that high priced inventory so we are nearly through, so we almost consumed potentially Rs.60 crore worth of that inventory in this quarter and we still might have about Rs.30 crore, Rs.32 crore of residual inventory, so this might have some impact, but yes we can look at getting back to the earlier levels quite soon. I believe October, November 2023 should be that point."

Segment-Level Demand & Pricing

SDA (Structure Directing Agents)

Electrolyte Salts

Chintan Shah: "We have been in this segment since 2013. It is a long-drawn process and again this is an equally strong entry barrier area for SDA because any change in quality parameters or any abnormality can lead to incidences with the battery. So, once you are qualified and the quality is accepted then it becomes really a very strong entry barrier area for the competition to get into it."

Flame Retardants

PASC & PTC

Chintan Shah: "This is kind of an unrealistically low pricing level and it is not sustainable for a long time and pricing pressure in lot of product or segments though we are fortunate that in certain PASC products where we are working one-on-one with the customer or on SDA and electrolytes also had entry barriers are really strong."

New Product Pipeline & Technology

Chintan Shah: "This can actually if we do this potentially then we would be the only producer of this key starting material for semiconductor in India."

Balance Sheet & Fundraising


Guidance & Commitments

CommitmentSpecificsTimeline
Gross margin recoveryReturn to earlier levels (~55%)October/November 2023
Dahej expanded capacity utilizationReach 65–70% on assembly sideFrom November 2023
Dahej expanded capacity utilizationReach 80–85%Next financial year
Electrolyte salts pilot trialDeliver first trial order from Dahej plantBy October 2023
Electrolyte salts commercial activityCommercial volumes to beginDecember 2023
SDA demand ramp-upStronger demand, formal approvals for 2 productsBy end of 2023
Agrochemical new productsCommercial supplies begin post-approvalLate December 2023 / early January 2024
Pharma intermediates (3 products)Commercial business begins post-validationEarly 2025
Flame retardants revenue₹25–40 croreFY24
Environmental clearance for new landReceive permissionPotentially August 2023
QIP fundraisingRaise ₹200 crore; promoter stake below 75%In process

Key Metrics

MetricQ1 FY24
Revenue from operations₹114.4 cr, +29% YoY from ₹88.4 cr
EBITDA₹21.3 cr, +40% YoY from ₹15.2 cr
EBITDA margin18.7%, +145 bps YoY from 17.2%
PAT₹9.5 cr, -3% YoY from ₹9.8 cr
PAT margin8.3% vs 11.1% in Q1 FY23
Exports₹88.9 cr, 78% of revenue from operations
Other income₹1 cr, -46% YoY
COGS+5.68% YoY
Employee benefit expenses+0.40% YoY
Other expenses-7.53% YoY
Depreciation₹6 cr vs ₹2.3 cr in Q1 FY23, +1.5% YoY
SDA segment revenue₹49.6 cr, ~43% of revenue
PTC segment revenue₹31.6 cr, ~28% of revenue
Pharma and Agro Intermediates and Specialty Chemicals revenue₹31 cr, ~27% of revenue
Electrolyte Salts revenue₹1.3 cr, ~1% of revenue
Installed reactor capacity500 kL, up from 294 kL; assembly lines increased from 27 to 39
Inventory (excl. spares and packing)₹120 cr as on June 2023, down ~₹12.5 cr from ₹132.5 cr as on March 2023
WIP & FG inventory consumed during quarter~₹60 cr, nearly two-thirds of ₹90–92 cr as on March 31, 2023
Working capital utilization71% of total sanction limits of ₹220 cr
IPO proceeds utilized₹200.2 cr of ₹207.28 cr net proceeds, 97% utilized as on June 30, 2023
Flame retardant revenue guidance FY24₹25–40 cr
Flame retardant price reduction~60% from peak
QIP fundraising target₹200 cr
Next phase capexNot more than ₹250 cr
Dahej expansion capitalized₹235 cr, 20-year assumed lifespan
Annual depreciation on all fixed assets~₹24 cr
Existing capacity utilization (pre-expansion)Near full
New capacity utilization (reactor side)Fully occupied temporarily, expected to drop to 30–35% by early September 2023
New capacity utilization (assembly side)Not yet started, expected 65–70% from November 2023
Expected capacity utilization (overall)80% within next year